Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report - Takeaways - MDSpire

Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report

  • By

  • Federica Gigli

  • Valentina Fabiola Sangiorgio

  • Valentina Tabanelli

  • Giuliana Gregato

  • Francesco Bertolini

  • Alessio Maria Edoardo Maraglino

  • Simona Sammassimo

  • Rocco Pastano

  • Enrico Derenzini

  • Corrado Tarella

  • July 2, 2026

  • 0 min

Share

  • 1

    Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for high-risk myelodysplastic syndrome and acute myeloid leukemia.

  • 2

    Post-transplant relapse in these patients is common and associated with significant morbidity and poor prognosis.

  • 3

    The combination of hypomethylating agents and venetoclax has shown encouraging results for post-transplant relapses.

  • 4

    A patient with high-risk MDS achieved complete remission after treatment with azacitidine, low-dose venetoclax, and donor lymphocyte infusion.

  • 5

    The patient remained in continuous complete remission for 24 months following the innovative treatment strategy.

Original Source(s)

Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report

  • by Federica Gigli, Valentina Fabiola Sangiorgio, Valentina Tabanelli, Giuliana Gregato, Francesco Bertolini, Alessio Maria Edoardo Maraglino, Simona Sammassimo, Rocco Pastano, Enrico Derenzini, Corrado Tarella

  • July 2, 2026

Related Content

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

  • 1 min
ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min
The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis